GO:0097690 iron ion transmembrane transporter inhibitor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0097690 defines a molecular function: binding to and stopping, preventing, or reducing the activity of an iron ion transmembrane transporter.
• This inhibitory activity is critical for controlling cellular iron uptake and distribution, preventing iron overload and oxidative stress.
• Key proteins involved include ferrireductases like STEAP3 and iron transporters such as SLC11A2 (DMT1), whose activities are modulated by inhibitors.
• Dysregulation of iron transport inhibitors is linked to colon tumorigenesis, neurodegeneration, and metabolic disorders.
• CRISPR knockout, point mutation, and overexpression models enable precise dissection of inhibitor-transporter interactions.
• EDITGENE provides custom cell models and screening services to study iron transport inhibition in disease contexts.
Description
Iron is an essential trace element required for numerous cellular processes, including oxygen transport, DNA synthesis, and mitochondrial respiration. However, excess free iron catalyzes the generation of reactive oxygen species (ROS) through Fenton chemistry, leading to oxidative damage to lipids, proteins, and DNA. Therefore, cells have evolved sophisticated mechanisms to regulate iron uptake and efflux, including inhibitor proteins that directly bind and suppress the activity of iron ion transmembrane transporters. The Gene Ontology term GO:0097690, iron ion transmembrane transporter inhibitor activity, captures this regulatory function at the molecular level. Understanding this activity is crucial for researchers studying iron homeostasis, because its dysregulation contributes to a wide range of pathologies, from cancer to neurodegeneration. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a comprehensive overview of the mechanisms, genes, and experimental models associated with GO:0097690.
iron ion transmembrane transporter inhibitor activity At A Glance
| GO ID | GO:0097690 |
|---|---|
| GO term | iron ion transmembrane transporter inhibitor activity |
| Ontology | molecular_function |
| Synonym | iron channel inhibitor activity |
| Major function | Binds to and stops, prevents, or reduces the activity of an iron ion transmembrane transporter |
| Related transporters | SLC11A2 (DMT1), SLC40A1 (ferroportin), STEAP3 |
| Associated processes | Iron homeostasis, oxidative stress response, mitochondrial iron handling |
| Disease relevance | Colon tumorigenesis, neurodegeneration, iron overload disorders |
What Is GO:0097690?
GO:0097690, iron ion transmembrane transporter inhibitor activity, is a molecular function defined as binding to and stopping, preventing, or reducing the activity of an iron ion transmembrane transporter. In other words, it is the activity of a protein that physically interacts with a transporter protein to block or diminish its ability to move iron ions across a membrane. This term is synonymous with iron channel inhibitor activity and is distinct from general iron binding or transport activities.
Why Is iron ion transmembrane transporter inhibitor activity Important in Cell Biology?
Iron ion transmembrane transporter inhibitor activity is essential for maintaining cellular iron balance and preventing toxicity. By modulating the activity of iron transporters, these inhibitors act as checkpoints that protect cells from iron overload and subsequent oxidative damage. In cancer, loss of such inhibitory control can lead to mitochondrial iron accumulation and tumorigenesis, as demonstrated in PINK1-deficient models. In neurodegenerative diseases, impaired iron transport inhibition may contribute to neuronal death. Thus, understanding GO:0097690 provides insights into fundamental iron biology and offers potential therapeutic targets for diseases linked to iron dysregulation.
• Prevents iron overload and oxidative stress by limiting excessive iron uptake.
• Regulates mitochondrial iron homeostasis, protecting against mitochondrial dysfunction.
• Modulates transferrin-independent iron transport pathways in cancer cells.
• Influences colon tumorigenesis through PINK1-mediated mitochondrial iron accumulation.
• Potential role in cuproptosis and bortezomib-induced neurotoxicity via ATF3/SLC31A1 axis.
• Involved in plasma membrane electron transport and growth control.
• Provides targets for therapeutic intervention in iron-related disorders.
• Enables precise dissection of iron transport mechanisms using CRISPR models.
What Happens During iron ion transmembrane transporter inhibitor activity?
Recognition and Binding to the Transporter
In simple terms: The inhibitor protein finds and attaches to the iron transporter.
The first step in iron ion transmembrane transporter inhibitor activity is the specific recognition of the target transporter. This involves electrostatic and hydrophobic interactions between the inhibitor and the transporter's transmembrane domains or regulatory regions. For example, ferrireductase activity in K562 cells is coupled to transferrin-independent iron transport, suggesting that inhibitor proteins may interact with transporters like SLC11A2 to modulate their function. Structural studies of STEAP enzymes reveal an elegant four-helical fold that facilitates electron transport across biomembranes, providing a template for understanding how inhibitor proteins might dock onto transporters.
Conformational Change and Blockade of Transport
In simple terms: The inhibitor changes the transporter's shape so it cannot carry iron.
Upon binding, the inhibitor induces conformational changes in the iron transporter that prevent substrate translocation. This may involve locking the transporter in an inward-facing or occluded state, thereby blocking the iron permeation pathway. In the context of plasma membrane oxidoreductase systems, electron and proton transport across the plasma membrane are tightly coupled to iron uptake, and inhibitors may disrupt this coupling. The oxidation of catalytically essential thiols in the cerebral sodium pump by iron-mediated oxidative stress illustrates how redox modifications can impair transporter function, a mechanism that may be exploited by inhibitor proteins.
Regulation of Iron Homeostasis
In simple terms: The inhibitor helps keep iron levels balanced inside the cell.
By reducing the activity of iron transporters, these inhibitors play a critical role in maintaining cellular iron homeostasis. In mitochondria, PINK1 deficiency leads to mitochondrial iron accumulation and colon tumorigenesis, indicating that PINK1 may normally inhibit mitochondrial iron transporters to prevent iron overload. Similarly, the ATF3/SLC31A1 axis mediates cuproptosis and bortezomib-induced peripheral neurotoxicity, highlighting the interplay between iron transport and cell death pathways. These examples underscore the importance of inhibitor activity in preventing pathological iron accumulation.
Integration with Cellular Signaling
In simple terms: The inhibitor works together with other signals to control iron.
Iron ion transmembrane transporter inhibitor activity is not an isolated event; it is integrated with cellular signaling pathways that sense iron status. For instance, coenzyme Q10 and plasma membrane oxidase are involved in growth control, and their activity may be modulated by iron transport inhibitors. The multifunctional octapeptide from Camellia oleifera globulin exhibits ferrous-transport capacity and inhibition mechanisms against Keap1 and angiotensin-I-converting enzyme, suggesting that natural peptides can act as transporter inhibitors. Such integration ensures that iron uptake is coordinated with cellular metabolic demands.
Key Genes Involved in GO:0097690 iron ion transmembrane transporter inhibitor activity
The following genes and proteins are directly or indirectly associated with iron ion transmembrane transporter inhibitor activity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PINK1 | Mitochondrial kinase that protects against iron accumulation | PINK1 deficiency facilitates mitochondrial iron accumulation and colon tumorigenesis |
| SLC11A2 (DMT1) | Divalent metal transporter 1; iron ion transmembrane transporter | Target of inhibitor activity; coupled to ferrireductase in K562 cells |
| STEAP3 | Ferrireductase involved in iron uptake | Structural fold facilitates electron transport; potential inhibitor target |
| SLC40A1 (ferroportin) | Iron exporter; transmembrane transporter | May be regulated by inhibitor proteins to control iron efflux |
| ATF3 | Stress-responsive transcription factor | ATF3/SLC31A1-mediated cuproptosis in neurotoxicity |
| SLC31A1 (CTR1) | Copper transporter; also affects iron homeostasis | Mediates cuproptosis and bortezomib-induced neurotoxicity |
| NOX family | NADPH oxidases; electron transport across membranes | Four-helical fold similar to STEAP; potential inhibitor interaction |
| Coenzyme Q10 | Electron carrier in plasma membrane oxidase | Involved in growth control and iron transport |
| Keap1 | Oxidative stress sensor | Inhibited by Camellia oleifera peptide with ferrous-transport capacity |
| ACE | Angiotensin-I-converting enzyme | Inhibited by multifunctional octapeptide |
| Cerebral sodium pump | Transmembrane ion transporter | Iron-mediated oxidative stress impairs its activity |
| Plasma membrane oxidase | Electron transport complex | Coupled to iron transport and growth control |
| Ferrireductase | Reduces ferric to ferrous iron for transport | Coupled to transferrin-independent iron transport |
| Transferrin receptor | Mediates transferrin-bound iron uptake | Indirectly affected by transporter inhibitors |
| Ferritin | Iron storage protein | Responds to changes in iron transport inhibition |
| Mitoferrin (SLC25A37) | Mitochondrial iron importer | Potential target of mitochondrial inhibitor activity |
| Hepcidin | Systemic iron regulator | May modulate transporter inhibitor expression |
| IRP1/2 | Iron regulatory proteins | Post-transcriptional regulators of iron transport genes |
How Is iron ion transmembrane transporter inhibitor activity Regulated?
The activity of iron ion transmembrane transporter inhibitors is regulated at multiple levels. Transcriptionally, stress-responsive factors such as ATF3 can modulate the expression of transporters and their inhibitors, as seen in bortezomib-induced neurotoxicity. Post-translationally, oxidative modifications of cysteine thiols can alter inhibitor function, as demonstrated for the cerebral sodium pump under iron-mediated oxidative stress. Additionally, mitochondrial quality control pathways involving PINK1 regulate mitochondrial iron accumulation, suggesting that PINK1 may control the activity of mitochondrial iron transporters or their inhibitors. Systemic iron status, sensed by iron regulatory proteins (IRPs), can also influence the expression of transport proteins and their inhibitors to maintain homeostasis.
iron ion transmembrane transporter inhibitor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PINK1 | Colon tumorigenesis; mitochondrial iron accumulation | PINK1 knockout colon cancer cell line |
| ATF3 | Bortezomib-induced peripheral neurotoxicity | ATF3 knockout or overexpression in neuronal cells |
| SLC31A1 | Cuproptosis; neurotoxicity | SLC31A1 knockout cells treated with bortezomib |
| SLC11A2 | Iron transport dysregulation; anemia | SLC11A2 mutant cell lines |
| STEAP3 | Iron overload; cancer | STEAP3 knockout or point mutant models |
Colon Tumorigenesis and Mitochondrial Iron Accumulation
PINK1 deficiency leads to mitochondrial iron accumulation and facilitates colon tumorigenesis, indicating that loss of PINK1-mediated inhibition of mitochondrial iron transport contributes to cancer development. This suggests that iron ion transmembrane transporter inhibitor activity is a tumor-suppressive mechanism, and its dysregulation may promote colorectal cancer.
Neurodegeneration and Bortezomib-Induced Neurotoxicity
The ATF3/SLC31A1 axis mediates cuproptosis and bortezomib-induced peripheral neurotoxicity, a condition where iron and copper homeostasis are disrupted. Inhibitors of iron transporters may protect against such neurotoxicity by limiting metal accumulation. Additionally, iron-mediated oxidative stress impairs the cerebral sodium pump, linking iron transport dysregulation to neurodegeneration.
Iron Overload and Oxidative Stress Disorders
Defects in iron ion transmembrane transporter inhibitor activity can lead to iron overload, causing oxidative damage to membrane lipids and proteins. This is relevant to conditions such as hemochromatosis and neurodegenerative diseases where iron accumulation is a hallmark. Natural peptides with ferrous-transport capacity and inhibitory activity, like those from Camellia oleifera, may offer therapeutic avenues.
From iron ion transmembrane transporter inhibitor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PINK1 increase mitochondrial iron transporter activity? | PINK1 knockout cell line |
| Can point mutations in SLC11A2 abolish inhibitor binding? | SLC11A2 point-mutant knock-in cells |
| Does overexpression of STEAP3 alter iron transport inhibition? | STEAP3 overexpression cell line |
| What is the effect of ATF3 on SLC31A1-mediated cuproptosis? | ATF3 knockout and overexpression models |
| Can natural peptides inhibit iron transporters? | Treatment of cells with Camellia oleifera octapeptide |
| How does iron-mediated oxidative stress affect sodium pump activity? | Cerebral sodium pump assays with iron exposure |
How to Study the iron ion transmembrane transporter inhibitor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality and modifier identification | Discovering regulators of iron transport inhibition |
| Ferrireductase assay | Reduction of ferric to ferrous iron | Measuring transporter-coupled activity |
| Radioactive iron uptake | Iron transport rate | Validating inhibitor efficacy |
| Cryo-EM | 3D structure of protein complexes | Visualizing inhibitor-transporter binding |
| Lipid peroxidation assay | Oxidative damage to membranes | Assessing iron-induced stress |
| Thiol oxidation assay | Oxidation of cysteine residues | Measuring redox modification of transporters |
| Peptide inhibition assay | Inhibitory activity of peptides | Screening natural compounds |
CRISPR-Based Genetic Screens
CRISPR knockout and activation screens can identify genes that regulate iron ion transmembrane transporter inhibitor activity. For example, a genome-wide knockout screen in colon cancer cells could reveal modifiers of PINK1-dependent mitochondrial iron accumulation. Such screens enable unbiased discovery of inhibitor proteins and their regulators.
Biochemical Transport Assays
Ferrireductase and iron transport assays using radioactive or fluorescent iron isotopes can measure the activity of transporters in the presence or absence of candidate inhibitors. The coupling of ferrireductase activity to transferrin-independent iron transport in K562 cells provides a classic assay system. These assays are essential for validating inhibitor function.
Structural and Biophysical Methods
Cryo-EM and X-ray crystallography can resolve the structure of inhibitor-transporter complexes. The four-helical fold in NOX and STEAP enzymes offers a structural framework for understanding how inhibitors might bind. Surface plasmon resonance and isothermal titration calorimetry can quantify binding affinities.
Oxidative Stress and Redox Measurements
Measuring lipid peroxidation and protein thiol oxidation can assess the consequences of iron transport inhibition. Iron-mediated oxidative stress-linked dysfunction of the cerebral sodium pump is a well-documented example. These methods link inhibitor activity to cellular redox balance.
How CRISPR Can Be Used to Study GO:0097690 iron ion transmembrane transporter inhibitor activity
Knockout
CRISPR knockout of genes encoding iron transporters or their inhibitors can reveal their causal roles in iron homeostasis. For example, PINK1 knockout leads to mitochondrial iron accumulation and tumorigenesis, demonstrating the importance of PINK1 in inhibiting mitochondrial iron transport. Knockout models are essential for loss-of-function studies.
Point Mutation
Introducing point mutations into transporter genes can disrupt inhibitor binding sites or catalytic residues. For instance, mutating the ferrireductase domain of STEAP3 could abolish its electron transport function, mimicking a loss of inhibition. Point mutation models help map precise interaction interfaces.
Knock-in
Knock-in of tagged transporters or inhibitors allows for real-time tracking and interaction studies. A GFP-tagged SLC11A2 knock-in cell line could be used to monitor transporter localization and inhibitor binding. This approach provides spatial and temporal resolution.
Overexpression
Overexpression of candidate inhibitor proteins can suppress iron transport and protect against iron overload. For example, overexpressing the Camellia oleifera octapeptide in cells may inhibit ferrous transport and reduce oxidative stress. Overexpression models are useful for gain-of-function studies.
How EDITGENE Supports iron ion transmembrane transporter inhibitor activity Research
Researchers studying iron ion transmembrane transporter inhibitor activity-related genes often need to determine whether a candidate gene is causally involved in iron homeostasis or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for iron ion transmembrane transporter inhibitor activity research.
Frequently Asked Questions About iron ion transmembrane transporter inhibitor activity
What is GO:0097690?
GO:0097690 is the Gene Ontology term for iron ion transmembrane transporter inhibitor activity, a molecular function where a protein binds to and reduces the activity of an iron ion transmembrane transporter.
What genes are involved in iron ion transmembrane transporter inhibitor activity?
Key genes include PINK1, SLC11A2 (DMT1), STEAP3, SLC40A1 (ferroportin), and ATF3, among others.
How does iron ion transmembrane transporter inhibitor activity prevent iron overload?
By binding to and inhibiting iron transporters, these proteins reduce iron uptake into cells, preventing toxic iron accumulation and oxidative stress.
What diseases are associated with defects in iron ion transmembrane transporter inhibitor activity?
Defects are linked to colon tumorigenesis, neurodegeneration, bortezomib-induced neurotoxicity, and iron overload disorders.
What research methods are used to study iron ion transmembrane transporter inhibitor activity?
Methods include CRISPR knockout screens, ferrireductase assays, radioactive iron uptake, cryo-EM, and oxidative stress measurements.
How can CRISPR models help study iron transport inhibitors?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of genes to test their role in iron transport inhibition.
What is the role of PINK1 in iron ion transmembrane transporter inhibitor activity?
PINK1 deficiency leads to mitochondrial iron accumulation, suggesting PINK1 normally inhibits mitochondrial iron transport and protects against tumorigenesis.
Can natural compounds inhibit iron transporters?
Yes, a multifunctional octapeptide from Camellia oleifera globulin exhibits ferrous-transport capacity and inhibitory activity against Keap1 and ACE, indicating natural inhibitors exist.
How is iron ion transmembrane transporter inhibitor activity regulated?
It is regulated transcriptionally by stress factors like ATF3, post-translationally by oxidative modifications, and systemically by iron regulatory proteins.
What cell models are available for studying iron transport inhibition?
EDITGENE provides custom knockout, point mutation, knock-in, and overexpression cell models for genes like PINK1, SLC11A2, and STEAP3.
Conclusion
Iron ion transmembrane transporter inhibitor activity (GO:0097690) is a critical molecular function that safeguards cells against iron overload and oxidative damage. Through the action of proteins such as PINK1, STEAP3, and natural peptides, this activity modulates iron transport to maintain homeostasis. Dysregulation of these inhibitors contributes to cancer, neurodegeneration, and metabolic disorders, making them attractive therapeutic targets. Leveraging CRISPR-based models and EDITGENE's services, researchers can dissect the precise mechanisms and develop novel interventions for iron-related diseases.
References
- 1. Arcos M et al.. 2025. PINK1-deficiency facilitates mitochondrial iron accumulation and colon tumorigenesis.. Autophagy 21(4):737-753 PMID: 39512202
- 2. Wang Y et al.. 2026. ATF3/SLC31A1-Mediated Cuproptosis Contributes to Bortezomib-Induced Peripheral Neurotoxicity and Intervention by (-)-Epigallocatechin Gallate.. Int J Mol Sci 27(8) PMID: 42074318
- 3. Crane FL et al.. 1994. Coenzyme Q10, plasma membrane oxidase and growth control.. Mol Aspects Med 15 Suppl:s1-11 PMID: 7752819
- 4. Omotayo TI et al.. 2015. Possible involvement of membrane lipids peroxidation and oxidation of catalytically essential thiols of the cerebral transmembrane sodium pump as component mechanisms of iron-mediated oxidative stress-linked dysfunction of the pump's activity.. Redox Biol 4:234-41 PMID: 25618580
- 5. Inman RS et al.. 1994. Extracellular ferrireductase activity of K562 cells is coupled to transferrin-independent iron transport.. Biochemistry 33(39):11850-7 PMID: 7918403
- 6. Crane FL et al.. 1991. Electron and proton transport across the plasma membrane.. J Bioenerg Biomembr 23(5):773-803 PMID: 1721049
- 7. Oosterheert W et al.. 2020. An Elegant Four-Helical Fold in NOX and STEAP Enzymes Facilitates Electron Transport across Biomembranes-Similar Vehicle, Different Destination.. Acc Chem Res 53(9):1969-1980 PMID: 32815713
- 8. Li Y et al.. 2025. Identification, In Silico Screening, Inhibition Mechanisms to Keap1 and Angiotensin-I-Converting Enzyme, and Ferrous-Transport Capacity of a Multifunctional Octapeptide from Camellia oleifera Globulin.. Plant Foods Hum Nutr 80(2):109 PMID: 40208474
